Lozenges and lozenge products

Abstract

The application discloses a lozenge and a lozenge product, comprising a lozenge body and a plurality of preset tearing structures arranged on the lozenge body, wherein the lozenge body comprises a substrate layer and a lozenge film layer, and the preset tearing structures are arranged on at least the substrate layer. The lozenge provided by the application is provided with the preset tearing structures, the preset tearing structures can reduce the tearing force of the lozenge, and are beneficial to users to tear and take a proper dose of the lozenge.

Description

Technical Field

[0001] This application relates to the fields of food or pharmaceutical technology, and in particular to a lozenge and a lozenge product. Background Technology

[0002] Traditional tobacco products like cigarettes release nicotine through combustion; however, combustion produces a significant amount of harmful substances that seriously impact health. Oral nicotine lozenges are a newer type of product. When placed in the mouth, they dissolve and release nicotine or its derivatives, which are then absorbed through the oral mucosa. They offer advantages such as precise dosage, rapid onset of action, and portability. Lozenges are tablet-shaped products, typically individually packaged or dispensed, with users usually taking only one tablet at a time. However, different users have different needs, and a fixed dosage may result in limited flexibility in dosage adjustments, affecting the user experience. Utility Model Content

[0003] This application provides a lozenge and a lozenge product to solve the problem that existing lozenges are single-tablet dosage forms with poor dispensing flexibility.

[0004] This application discloses a lozenge, including a lozenge body and a plurality of preset tear structures disposed on the lozenge body, wherein the lozenge body includes a base layer and a lozenge film layer, and at least the base layer is provided with the preset tear structures.

[0005] In one implementation of this application, there are sawtooth structures, single-line structures, parallel-line structures, dot-shaped microporous line structures, and mesh structures.

[0006] In one implementation of this application, the oral patch body includes at least two base layers, wherein at least one base layer is a water-permeable layer, the oral membrane layer is disposed between two adjacent base layers, and each base layer is provided with the preset tear structure.

[0007] In one implementation of this application, the mouthpiece body includes at least two mouthpiece film layers, and an isolation layer is provided between at least one group of adjacent mouthpiece film layers. The isolation layer is provided with a preset tear structure corresponding to the base layer.

[0008] In one implementation of this application, the oral membrane layer is provided with the preset tear structure corresponding to the base layer.

[0009] In one implementation of this application, the base layer is a flexible base, and the mouthpiece can be rolled into a roll structure.

[0010] In one implementation of this application, the mouthwash body further includes an anti-adhesion layer, which is disposed on the outermost layer of the mouthwash body.

[0011] In one implementation of this application, the anti-stick layer includes at least one of a silicone paper anti-stick layer, a silica anti-stick layer, and a polytetrafluoroethylene anti-stick layer.

[0012] In one implementation of this application, the tearing force at the preset tearing structure is 15cN to 100cN.

[0013] This application also discloses a lozenge article comprising a pushing mechanism and a lozenge as described above, wherein the lozenge is disposed within the pushing mechanism, and the pushing mechanism is configured to push a portion of the length of the lozenge to the outside of the pushing mechanism.

[0014] Due to the adoption of the above technical solutions, the beneficial effects of this application are as follows:

[0015] The lozenge of this application has a preset tearing structure on the lozenge body. The preset tearing structure can reduce the tearing force of the lozenge, which is conducive to users tearing out the appropriate dose of lozenge according to different dosage needs, and the use is highly flexible. Attached Figure Description

[0016] Figure 1 This is a schematic diagram of the pre-designed tear structure of the lozenge involved in this application.

[0017] Figure 2 This is a schematic diagram of the layered structure of a lozenge body according to a specific embodiment of this application.

[0018] Figure 3 This is a schematic diagram of the layered structure of a lozenge body according to another specific embodiment of this application.

[0019] Figure 4 This is a schematic diagram of the layered structure of a mouth lozenge body according to another specific embodiment of this application.

[0020] Figure 5 This is a schematic diagram of the structure of the oral lozenge product involved in this application.

[0021] Explanation of reference numerals in the attached drawings: 10… lozenge, 11… lozenge body, 12… pre-set tear structure, 111… base layer, 112… oral film layer, 113… isolation layer, 114… anti-stick layer, 100… lozenge product, 20… pushing mechanism, 21… driving part. Detailed Implementation

[0022] The present application will now be described in further detail with reference to specific embodiments and accompanying drawings. In the following embodiments, many details are described to facilitate a better understanding of the present application. However, those skilled in the art will readily recognize that some features may be omitted in different situations, or may be replaced by other materials or methods. In some cases, certain operations related to the present application are not shown or described in the specification. This is to avoid obscuring the core parts of the present application with excessive description. For those skilled in the art, detailed description of these related operations is not necessary; the relevant operations can be fully understood based on the description in the specification and general technical knowledge in the art.

[0023] Furthermore, the features, operations, or characteristics described in the specification can be combined in any suitable manner to form various embodiments. At the same time, the steps or actions in the method description can be rearranged or adjusted in a manner obvious to those skilled in the art. Therefore, the various orders in the specification and drawings are only for the clear description of a particular embodiment and do not imply a necessary order, unless otherwise stated that a particular order must be followed.

[0024] Most existing nicotine lozenges are single-tablet formulations with a fixed dosage, preventing users from flexibly adjusting the amount to suit their needs. Furthermore, individual differences in nicotine sensitivity mean that a fixed dosage may lead to a poor user experience. In addition, existing lozenges lack a segmented structure, making them difficult to tear, and the resulting fragmented structure can alter the taste or cause loss of active ingredients, hindering the "one tablet, multiple segments" usage approach and limiting flexible use in various scenarios.

[0025] In view of this, this application creatively proposes a mouthwash with a pre-set tearing structure, which allows users to tear a mouthwash of a suitable length to meet their needs.

[0026] Figure 1 This is a schematic diagram of the pre-set tear structure 12 of the mouthpiece body 11 involved in this application. In a specific embodiment, the mouthpiece 10 includes a mouthpiece body 11 and a pre-set tear structure 12.

[0027] In one specific embodiment, the oral tablet body 11 is in the form of a sheet or a film.

[0028] In one specific embodiment, the thickness of the mouthpiece body 11 can be from 10 μm to 1000 μm. For example, the thickness of the mouthpiece body 11 can be 10 μm, 50 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm or 1000 μm.

[0029] In one specific embodiment, the width of the mouthpiece body 11 can be 5mm to 20mm. For example, the width of the mouthpiece body 11 can be 5mm, 10mm, 15mm or 20mm.

[0030] In one specific embodiment, a pre-set tear structure 12 is disposed on the mouthpiece body 11.

[0031] In one specific embodiment, the number of preset tear structures 12 can be multiple.

[0032] In one specific embodiment, the pre-set tear structure 12 may be parallel to the width direction Y of the mouthpiece body 11. The pre-set tear structure 12 may be distributed along the length direction X of the mouthpiece body 11.

[0033] In some embodiments, the preset tear structure 12 may also form an angle with the width direction Y of the mouthpiece body 11, such as 10°, 20°, 30°, 45°, etc.

[0034] In some embodiments, the preset tear structure 12 may also be parallel to the length direction X of the mouthpiece body 11 and distributed along the width direction Y of the mouthpiece body 11.

[0035] In one specific embodiment, the pre-defined tear structures 12 are periodically distributed along the length direction X of the mouthpiece body 11. The distance between adjacent pre-defined tear structures 12 can be 10mm to 40mm. For example, the distance between adjacent pre-defined tear structures 12 can be 10mm, 15mm, 20mm, 25mm, 30mm, 35mm or 40mm.

[0036] like Figure 1 As shown, in one specific embodiment, the preset tear structure 12 can be selected from any one or more of the following: serrated structure, single-line structure, parallel-line structure, dotted microporous line structure, and mesh structure. A serrated structure refers to a serrated structure. A single-line structure refers to a structure in the form of a single straight line. A parallel-line structure refers to a structure in the form of two parallel straight lines. A dotted microporous line structure refers to a structure in the form of "dashed lines" formed by multiple through holes. A mesh structure refers to a micro-line structure in the form of a cross-shaped structure. The preset tear structure 12 can also be selected from other shapes or structures, for example, it can be a hidden (visually invisible) structure.

[0037] In one specific embodiment, the width of the preset tear structure 12 can be 0.2mm to 1.5mm. For example, the width of the preset tear structure 12 can be 0.2mm, 0.3mm, 0.5mm, 0.8mm, 1mm, 1.2mm, or 1.5mm.

[0038] In one specific embodiment, the depth of the preset tear structure 12 can be from 10 μm to 900 μm. For example, the depth of the preset tear structure 12 can be 10 μm, 50 μm, 100 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm or 900 μm.

[0039] In one specific embodiment, the depth of the preset tear structure 12 can be less than or equal to the thickness of the mouthpiece body 11. For example, the depth of the preset tear structure 12 can be 70% to 95% of the thickness of the mouthpiece body 11.

[0040] In one specific embodiment, when the preset tear structure 12 is a dot-shaped microporous line structure, the micropores can be through holes. The shape of the micropores can be circular, elliptical, or other shapes.

[0041] In one specific embodiment, the parameters of the preset tear structure 12 can be any one of those in the table below:

[0042]

[0043] In one specific embodiment, this application systematically establishes a parameter system for the preset tear structure 12, including texture width, texture depth, pore size, bridge width, etc., and controls the tearing force to achieve the effect that the mouthpiece 10 can be continuously pushed, stably broken, and will not break prematurely, thus ensuring the user experience and product safety.

[0044] In one specific embodiment, the preset tear structure 12 can be obtained by processing the oral lozenge body 11.

[0045] In one specific embodiment, the processing method of the preset tear structure 12 can be selected from: laser drilling, die cutting punching, needle wheel punching, hot pressing, cold molding, embossing roller, engraving and indentation, and electric hot knife segment drilling.

[0046] In one specific embodiment, the tearing force at the preset tear structure 12 can be 15cN to 100cN. For example, the tearing force at the tear structure 2 can be 15cN, 20cN, 25cN, 30cN, 35cN, 40cN, 45cN, 50cN, 55cN, 60cN, 65cN, 70cN, 75cN, 80cN, 85cN, 90cN, 95cN, or 100cN.

[0047] Figure 2 This is a schematic diagram of the layered structure of the mouthpiece body 11 according to a specific embodiment of this application.

[0048] In one specific embodiment, the lozenge body 11 may include a base layer 111 and a lozenge film layer 112. The base layer 111 can provide mechanical strength and support for the lozenge film layer 112.

[0049] In one specific embodiment, the oral film layer 112 typically includes a film-forming agent, a plasticizer, and a functional substance. The film-forming agent may be selected from: hydroxypropyl methylcellulose, polyvinyl alcohol, pullulan, gelatin, chitosan, polyvinylpyrrolidone, and sodium carboxymethyl cellulose. The plasticizer may be selected from: glycerin, sorbitol, propylene glycol, polyethylene glycol, and xylitol. The functional substance may include active ingredients and / or flavoring agents.

[0050] In some embodiments, the active substance may include nicotine and / or nicotine derivatives. In some embodiments, the active substance may also include substances with specific pharmaceutical properties, or other substances with specific active properties, such as caffeine, theophylline, capsaicin, tea polyphenols, etc.

[0051] In some embodiments, the flavoring agent may include at least one of the following: flavoring agent, cooling agent, and flavoring agent.

[0052] In one specific embodiment, nicotine may include natural nicotine and synthetic nicotine. Nicotine derivatives may include one or more of the following: nicotine salts, nicotine in a matrix such as a glycobase or an organometallic complex, nicotine-resin combinations, nicotine inclusion complexes, and non-covalently bound nicotine. Non-covalently bound nicotine may include nicotine lactate, nicotine malate, nicotine salicylate, nicotine cyclodextrin-encapsulated complexes, nicotine hydrochloride, nicotine dihydrochloride, nicotine tartrate, nicotine tartrate dihydrate, nicotine sulfate, nicotine zinc chloride, and nicotine benzoate. Nicotine derivatives may also include nicotine containing substituents, such as one or more mixtures of hexamethylnicotine, hexamethylnicotine lactate, hexamethylnicotine malate, hexamethylnicotine salicylate, hexamethylnicotine cyclodextrin encapsulated complex, hexamethylnicotine hydrochloride, hexamethylnicotine dihydrochloride, hexamethylnicotine tartrate, hexamethylnicotine tartrate dihydrate, hexamethylnicotine sulfate, hexamethylnicotine zinc chloride, and hexamethylnicotine benzoate.

[0053] In one specific embodiment, the sweetener may include at least one selected from xylitol, sorbitol, mannitol, iodine, lactitol, maltitol, isomaltitol, hydrogenated starch hydrolysate, erythritol, maltodextrin, aspartame, acesulfame potassium, sodium saccharin, sucralose, neotame, cyclamate, alitane, steviol glycosides, arabinitol, and monk fruit sweetener. The sweetener may also be selected from other edible-grade substances, which will not be elaborated upon herein.

[0054] In one specific embodiment, the flavoring agent may include at least one selected from fragrances, natural essential oils, and natural extracts. The fragrance is an edible fragrance, which may include at least one selected from bergamot, eucalyptus, citrus, lemon, peppermint, peppermint, menthol, licorice, wintergreen, tobacco, coffee, vanilla, lime, apple, peach, mango, cherry, blueberry, strawberry, cola, cinnamon, pandan, and watermelon. The fragrance may also be other types of edible fragrances, which will not be elaborated upon herein.

[0055] In one specific embodiment, the cooling agent may include at least one of menthol, menthol derivatives, WS-3, and WS-23.

[0056] In one specific embodiment, the oral membrane layer 112 may have a predetermined tear structure 12.

[0057] In one specific embodiment, the substrate 111 can serve as a coating substrate, and the film-forming liquid for forming the oral film layer 112 can be directly coated onto the substrate 111.

[0058] In one specific embodiment, the base layer 111 is a water-permeable layer. Saliva can pass through the base layer 111.

[0059] In one specific embodiment, the base layer 111 can provide a sustained-release effect. For example, the base layer 111 can be placed in the oral cavity together with the oral film layer 112. The base layer 111 is located between the oral mucosa and the oral film layer 112, and can slow down the passage rate of saliva to achieve a sustained-release effect of functional substances in the oral film layer 112.

[0060] In one specific embodiment, the substrate layer 111 can be selected from one of the following: nonwoven fabric, thermoplastic resin film, edible paper. For example, the substrate layer 111 can be polylactic acid nonwoven fabric (PLA), cellulose acetate fabric, polyvinyl alcohol film (PVOH film), starch-based film, low-basis-weight water-soluble paper, glycerol-modified edible film paper, etc.

[0061] In one specific embodiment, the thickness of the substrate layer 111 can be from 20 μm to 1000 μm. For example, the thickness of the substrate layer 111 can be 20 μm, 50 μm, 50 μm, 100 μm, 200 μm, 500 μm or 1000 μm.

[0062] In one specific embodiment, the base layer 111 may have a pre-defined tear structure 12.

[0063] In one specific embodiment, the preset tear structure 12 on the substrate layer 111 can be correspondingly configured with the preset tear structure 12 on the oral film layer 112. Corresponding configuration means that, when projected along the thickness direction of the oral film 10, the preset tear structure 12 on the substrate layer 111 and the preset tear structure 12 on the oral film layer 112 at least partially overlap or completely overlap. For example, the preset tear structure 12 can be obtained by simultaneously processing the laminated oral film layer 112 and the substrate layer 111.

[0064] In one specific embodiment, the base layer 111 can be pre-processed, and then a mouth film layer 112 can be formed by coating the base layer 1110 to obtain a mouthpiece body 11 containing a predetermined tear structure 12. For example, embossed lines can be formed in the base layer 111, and after coating, the embossed lines are embedded in the mouthpiece body 11 to form the predetermined tear structure 12.

[0065] In one specific embodiment, the mouthpiece body 11 may include at least two base layers 111, and a mouthpiece film layer 112 is disposed between two adjacent base layers 111. Each base layer 111 may have a corresponding preset tear structure 12. "Correspondingly" means that, projected along the thickness direction of the mouthpiece 10, the preset tear structures 12 on each base layer 111 at least partially overlap or completely overlap.

[0066] In one specific embodiment, the oral tablet body 11 may sequentially include: a base layer 111, an oral film layer 112, and a base layer 111.

[0067] In one specific embodiment, the base layer 111 can be a flexible base. The mouthpiece 10 or the mouthpiece body 11 can be wound into a roll structure.

[0068] Figure 3 This is a schematic diagram of the layered structure of the mouthpiece body 11 according to another specific embodiment of this application.

[0069] like Figure 3 As shown, in one specific embodiment, the mouthpiece body 11 includes at least two mouthpiece film layers 112. An isolation layer 113 is provided between at least one set of adjacent mouthpiece film layers 112. The isolation layer 113 has a preset tear structure 12 corresponding to the base layer 111. "Corresponding" means that, projected along the thickness direction of the mouthpiece 10, the preset tear structure 12 on the base layer 111 and the preset tear structure 12 on the isolation layer 113 at least partially overlap or completely overlap.

[0070] In one specific embodiment, the mouthpiece body 11 may sequentially include: a base layer 111, a mouthpiece film layer 112, a separating layer 113, a mouthpiece film layer 112, and a base layer 111.

[0071] Figure 4This is a schematic diagram of the layered structure of the mouthpiece body 11 according to another specific embodiment of this application.

[0072] like Figure 4 As shown, in one specific embodiment, the mouthpiece body 11 may also have an anti-adhesion layer 114. The anti-adhesion layer 114 is used to reduce adhesion between mouthpiece bodies 11, reduce friction between mouthpiece bodies 11, improve durability and stability, and extend service life.

[0073] In one specific embodiment, there may be multiple anti-stick layers 114.

[0074] In one specific embodiment, the anti-sticking layer 114 is disposed on the outermost layer of the lozenge body 11.

[0075] In one specific embodiment, the mouthpiece body 11 may sequentially include: an anti-adhesion layer 114, a mouthpiece film layer 112, and a base layer 111.

[0076] In one specific embodiment, the mouthpiece body 11 may sequentially include: an anti-adhesion layer 114, a base layer 111, a mouthpiece film layer 112, a base layer 111, and an anti-adhesion layer 114.

[0077] In one specific embodiment, the mouthpiece body 11 may sequentially include: an anti-adhesion layer 114, a base layer 111, a mouthpiece film layer 112, a release layer 113, a mouthpiece film layer 112, a base layer 111, and an anti-adhesion layer 114.

[0078] In one specific embodiment, the anti-stick layer 114 may include at least one of a silicone paper anti-stick layer, a silica anti-stick layer, and a polytetrafluoroethylene anti-stick layer.

[0079] In one specific embodiment, the anti-adhesive layer 114 may have a preset tear structure 12. The preset tear structure 12 on the base layer 111 may coincide with the preset tear structure 12 on the anti-adhesive layer 114. For example, the preset tear structure 12 can be obtained by processing the laminated anti-adhesive layer 114 and the base layer 111.

[0080] In one specific embodiment, a user can take a specific length of the lozenge 10 according to their own needs. For example, the lozenge 10 can be torn apart by one or two preset tear structures 12 for use.

[0081] Figure 5 This is a schematic diagram of the structure of the oral lozenge product 100 involved in this application. This application also relates to an oral lozenge product 100.

[0082] In one embodiment, the lozenge article 100 may include a pushing mechanism 20 and the aforementioned lozenge 10. The pushing mechanism 20 is configured to push the lozenge 10 of a predetermined length to the outside of the article 100.

[0083] In one specific embodiment, the pushing mechanism 20 may include a driving unit. The driving unit can trigger the pushing mechanism 20 to operate, pushing out the mouthpiece 10.

[0084] In one specific embodiment, the lozenge 10 can be contained within the lozenge product 100 by a winding method, and the inside of the pushing mechanism 20 may include mechanisms such as ratchet, spring or rack to realize the quantitative pushing of the lozenge.

[0085] In one specific embodiment, the driving unit can take the form of a push-button, a rotary knob, a sliding groove key, or a sensing component. For example, pressing the push-button sequentially releases a fixed advance mechanism, causing the mouthpiece 10 to advance a predetermined length. A rotary knob can drive the roll of the mouthpiece 10 to rotate, enabling the mouthpiece 10 to be extended segment by segment. The sensing component can drive the release mechanism to intermittently advance the mouthpiece 10 by sensing the user's operation or changes in membrane tension; alternatively, a microcontroller can control a motor or coil actuator to precisely release the mouthpiece 10 to a predetermined length.

[0086] The present application will be further described in detail below through specific experimental procedures and experimental data examples. The following examples are for further illustration only and should not be construed as limiting the present application. In these examples, unless otherwise specified, all reagents and instruments used are commercially available, and all experimental operations are performed in accordance with product instructions and standard experimental procedures.

[0087] Example 1:

[0088] The pre-designed tear structure in Example 1 is a linear groove structure. Specific process parameters are shown in the table below:

[0089]

[0090]

[0091] Example 2:

[0092] The pre-designed tear structure in Example 2 is a circular hole with a dashed line structure. Specific process parameters are shown in the table below:

[0093]

[0094] Example 3:

[0095] The difference from Example 1 is that no anti-stick layer is provided.

[0096] Example 4:

[0097] The difference from Example 2 is that no anti-stick layer is provided.

[0098] In Examples 1 to 4, the substrate layer used was a PVOH film. The composition of the anti-adhesive layer used in Examples 1 to 4 included: 40% by mass of silica, 30% by mass of dimethyl silicone oil, and 30% by mass of glycerin. The film-forming solution formulations of the lozenge body used in Examples 1 to 4 are shown in the table below.

[0099] Hydroxypropyl methylcellulose (HPMC) Viscosity 6cP 7％ Propylene glycol pharmaceutical grade 2％ Nicotine salts butyrate 6％ essence Fruit flavor 1.5％ pure water - 83.5％

[0100] Stability test:

[0101] Environmental aging tests were conducted on the lozenges prepared in Examples 1 to 4. The testing equipment was a constant temperature and humidity aging chamber, and the test conditions included: 45℃, fixed humidity (90% RH), and aging for 7 days. Ten samples were tested for each example. The test content was: after aging, the interlayer delamination adhesion of each example was observed, and the stability of different structures under aging conditions was evaluated. Test results: The addition of the anti-adhesive layer has a significant impact on the stability and product life of the strip lozenges. The pass rate of Example 1 was 100%, and the film structure of the lozenges after environmental aging test remained intact without adhesion; the pass rate of Example 2 was 90%; the pass rate of Example 3 was 40%; and the pass rate of Example 4 was 20%. It can be seen that the anti-adhesive layer can effectively avoid film adhesion and delamination problems, exhibiting a longer product life and a higher pass rate, and can reduce the occurrence of interlayer adhesion and subsequent performance degradation.

[0102] Tear resistance test:

[0103] Tear strength tests were conducted on the lozenges prepared in Examples 1 and 2. The testing equipment was a precision tensile testing machine. The test conditions included: clamping width of 10 mm, tearing speed of 50 mm / min, ambient temperature of 23 ± 2℃, and relative humidity of 50 ± 5%. The results are shown in the table below.

[0104] Example 1 Linear embossing 42.3 2.5 Example 2 dotted line of round hole 55.6 3.2

[0105] Results analysis showed that Example 1 (linear groove structure) had a tear force controlled in the range of 40-45 cN, which is considered medium to low tear force, suitable for one-handed tearing operations. The tear edge was regular, and the breaking process progressed linearly, making it more user-friendly for users with low grip strength (such as women / the elderly). Example 2 (circular hole dotted line structure) had a slightly higher tear force, with an average of 55.6 cN. The tearing sensation was more distinct, with a "slight segmented blocking sensation," which could improve the user's sense of control during breakage. It is suitable for medium-thickness film structures. The standard deviation was slightly larger, possibly due to slight differences in the thickness of the local hole bridge cross-section.

[0106] The above description, in conjunction with specific embodiments, provides a further detailed explanation of this application and should not be construed as limiting the specific implementation of this application to these descriptions. For those skilled in the art, various simple deductions or substitutions can be made without departing from the concept of this application, and all such modifications or substitutions should be considered within the scope of protection of this application.

Claims

1. A lozenge, characterized in that, The device includes a mouthpiece body and a plurality of preset tear structures disposed on the mouthpiece body, wherein the mouthpiece body includes a base layer and a mouthpiece film layer, and at least the base layer is provided with the preset tear structures.

2. The lozenge as described in claim 1, characterized in that, The preset tearing structure is selected from any one or more of the following: serrated structure, single-line structure, parallel line structure, dotted microporous line structure, and mesh structure.

3. The lozenge as described in claim 1, characterized in that, The oral tablet body includes at least two base layers, wherein at least one base layer is a water-permeable layer, the oral membrane layer is disposed between two adjacent base layers, and each base layer is provided with the preset tear structure.

4. The lozenge as described in claim 1, characterized in that, The oral tablet body includes at least two oral film layers, and an isolation layer is provided between at least one pair of adjacent oral film layers. The isolation layer is provided with a preset tear structure corresponding to the base layer.

5. The lozenge as described in claim 1, characterized in that, The oral membrane layer is provided with a preset tear structure corresponding to the base layer.

6. The lozenge as described in claim 1, characterized in that, The base layer is a flexible base, and the oral tablet can be rolled into a roll structure.

7. The lozenge as described in claim 1, characterized in that, The lozenge body also includes an anti-sticking layer, which is disposed on the outermost layer of the lozenge body.

8. The lozenge as described in claim 7, characterized in that, The anti-stick layer includes at least one of silicone paper anti-stick layer, silica anti-stick layer and polytetrafluoroethylene anti-stick layer.

9. The lozenge according to any one of claims 1 to 8, characterized in that, The tearing force at the preset tearing structure is 15cN to 100cN.

10. A lozenge product, characterized in that, The lozenge article includes a pushing mechanism and a lozenge as described in any one of claims 1 to 9, the lozenge being disposed within the pushing mechanism, the pushing mechanism being configured to push a portion of the length of the lozenge to the outside of the pushing mechanism.

Images